EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque-Pereira iD, Christine Leopold, Patrick C Souverein iD, Aukje K Mantel-Teeuwisse, Marie L De Bruin iD

British Journal of Clinical Pharmacology · 29.04.2026

DOI: 10.1002/bcp.70580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 29.04.2026. Verfasst von Comfort Kunak Ogar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlan…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.

Methods

We descriptively analysed AEFIs to nOPV2 and other vaccines reported to VigiBase from January 1, 2010 to December 31, 2023. Proportional Reporting ratios (PRRs) at Medical Dictionary for Regulatory Activities (MedDRA) higher level group term (HLGT) compared signals of disproportionate reporting (SDR) between nOPV2 and two comparators.

Results

In total, 409 001 AEFIs were included (nOPV2 specific AEFIs: n = 18 911 [4.6%]), of which 54.0% males (n = 10 209) and 22.6% serious (n = 4283). Most events had resolved (n = 9418, 49.8%) or were resolving (n = 6239, 33.0%) at reporting. Body temperature conditions, gastrointestinal and respiratory tract‐related events were most reported to nOPV2. Five ‘novel’, mostly non‐serious SDRs were identified ‐ oral soft tissue conditions (PRR: 2.47, 95% CI: 1.71–3.59), haemoglobinopathies (PRR: 31.53, 95% CI: 3.38–312.72), malabsorption conditions (PRR: 4.65, 95% CI: 1.79–12.09), neoplasm‐related morbidities (PRR: 3.61, 95% CI: 1.44–9.11) and skin and subcutaneous tissue infections and infestations NEC (PRR: 3.55, 95% CI: 2.61–4.82). Among the serious events, nervous system‐related events were reported more. Conclusion nOPV2 appears to retain a positive safety profile in real‐world use. We support its continued use for cVDPV outbreak response and advocate continued monitoring as coverage increases and reporting is no longer mandated.

Schlagwörter

Stichwörter der Autor:innen

VigiBaseadverse events following immunization (AEFI)novel oral polio vaccine type 2 (nOPV2)safety analysissignals of disproportionate reporting

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.
  • Department of Global Health and Manufacturing Services, United States Pharmacopeia (USP), Rockville, Maryland, USA.
  • Department of Data Science and Biostatistics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Leonardo Roque-Pereira, Patrick C Souverein, Marie L De Bruin

Zitieren

APA

Ogar, C. K., Sisay, M. M., Roque-Pereira, L., Leopold, C., Souverein, P. C., Mantel-Teeuwisse, A. K., & De Bruin, M. L. (2026). Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70580

Vancouver

Ogar CK, Sisay MM, Roque-Pereira L, Leopold C, Souverein PC, Mantel-Teeuwisse AK, et al. Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70580

BibTeX
@article{Ogar2026,
  author = {Ogar, Comfort Kunak and Sisay, Malede Mequanent and Roque-Pereira, Leonardo and Leopold, Christine and Souverein, Patrick C and Mantel-Teeuwisse, Aukje K and De Bruin, Marie L},
  title = {Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70580}
}
Kostenlos starten →